Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 11/2013

01.11.2013 | Original Paper

Loss of chromosome 4 correlates with better long-term survival and lower relapse rate after R0-resection of colorectal liver metastases

verfasst von: Nadine Aust, Silke Schüle, Annelore K. Altendorf-Hofmann, Yuan Chen, Thomas Knösel, Olaf Dirsch, Utz Settmacher, Anja Weise, Kristin Mrasek, Thomas Liehr

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Liver metastases are the major cause of cancer-related death in colorectal cancer patients with a tendency to recur in over 50 % of the cases even after curatively intended surgery. Prognosis after liver resection, however, can neither be based on macroscopic or light microscopic evaluation of the metastases nor on clinical data alone. This is a pilot study in order to determine a potential influence of chromosomal aberrations on overall survival and relapse rate after curative liver resection.

Methods

Twenty randomly selected cases (10 patients with a survival of more and 10 patients with a survival of less than 5 years after resection) were studied by array comparative genomic hybridization.

Results

The distributions concerning age, gender, stage and grading of primary tumor, percentage of patients with chemotherapy, number and distribution of the liver metastases, Nordlinger and Fong scores showed no differences between long- and short-term survivors and no correlation to any chromosomal aberration. However, the relapse rate of patients with (partial) monosomy 4 was lower and the long-time survival better than in the other patients.

Conclusions

Loss of chromosome 4 in colorectal liver metastases seems not only to be associated with the progression of the primary tumor as reported in the literature, but also with the long-term survival and the cumulative relapse rate after complete resection of colorectal liver metastases.
Literatur
Zurück zum Zitat Blazer DG 3rd, Kishi Y et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26(33):5344–5351PubMedCrossRef Blazer DG 3rd, Kishi Y et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26(33):5344–5351PubMedCrossRef
Zurück zum Zitat Brosens RP, Belt EJ et al (2010) Deletion of chromosome 4q predicts outcome in stage II colon cancer patients. Anal Cell Pathol 33(2):95–104 Brosens RP, Belt EJ et al (2010) Deletion of chromosome 4q predicts outcome in stage II colon cancer patients. Anal Cell Pathol 33(2):95–104
Zurück zum Zitat Bruin SC, Klijn C et al (2010) Specific genomic aberrations in primary colorectal cancer are associated with liver metastases. BMC Cancer 10:662PubMedCrossRef Bruin SC, Klijn C et al (2010) Specific genomic aberrations in primary colorectal cancer are associated with liver metastases. BMC Cancer 10:662PubMedCrossRef
Zurück zum Zitat Chua TC, Saxena A et al (2010) Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17(2):492–501PubMedCrossRef Chua TC, Saxena A et al (2010) Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17(2):492–501PubMedCrossRef
Zurück zum Zitat de Haas RJ, Wicherts DA et al (2010) Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 17(4):1010–1023PubMedCrossRef de Haas RJ, Wicherts DA et al (2010) Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 17(4):1010–1023PubMedCrossRef
Zurück zum Zitat Diep CB, Kleivi K et al (2006) The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosom Cancer 45(1):31–41PubMedCrossRef Diep CB, Kleivi K et al (2006) The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosom Cancer 45(1):31–41PubMedCrossRef
Zurück zum Zitat Fong Y, Fortner J et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309–318 (discussion 318–321) Fong Y, Fortner J et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309–318 (discussion 318–321)
Zurück zum Zitat Gordon KJ, Kirkbride KC et al (2009) Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis 30(2):238–248PubMedCrossRef Gordon KJ, Kirkbride KC et al (2009) Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis 30(2):238–248PubMedCrossRef
Zurück zum Zitat Iwatsuki S, Dvorchik I et al (1999) Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 189(3):291–299PubMedCrossRef Iwatsuki S, Dvorchik I et al (1999) Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 189(3):291–299PubMedCrossRef
Zurück zum Zitat Knosel T, Schluns K et al (2004) Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. Neoplasia 6(1):23–28PubMed Knosel T, Schluns K et al (2004) Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. Neoplasia 6(1):23–28PubMed
Zurück zum Zitat Koch M, Kienle P et al (2005) Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg 241(2):199–205PubMedCrossRef Koch M, Kienle P et al (2005) Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg 241(2):199–205PubMedCrossRef
Zurück zum Zitat Konopke R, Kersting S et al (2009) Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 29(1):89–102PubMedCrossRef Konopke R, Kersting S et al (2009) Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 29(1):89–102PubMedCrossRef
Zurück zum Zitat Lee WS, Kim MJ et al (2008) Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbeck’s Arch Surg 393(1):13–19CrossRef Lee WS, Kim MJ et al (2008) Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbeck’s Arch Surg 393(1):13–19CrossRef
Zurück zum Zitat Liehr T, Manvelyan M (2009) Characterization of archived formalin-fixed/paraffin-embedded or cryofixed tissue, including nucleus extraction. In: Liehr T (ed) Fluorescence in situ hybridization (FISH)—application guide. Springer, Berlin, pp 147–156CrossRef Liehr T, Manvelyan M (2009) Characterization of archived formalin-fixed/paraffin-embedded or cryofixed tissue, including nucleus extraction. In: Liehr T (ed) Fluorescence in situ hybridization (FISH)—application guide. Springer, Berlin, pp 147–156CrossRef
Zurück zum Zitat Mollevi DG, Serrano T et al (2007) Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis 28(6):1241–1246PubMedCrossRef Mollevi DG, Serrano T et al (2007) Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis 28(6):1241–1246PubMedCrossRef
Zurück zum Zitat Munoz-Bellvis L, Fontanillo C et al (2012) Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays. Modern Pathol 25(4):590–601CrossRef Munoz-Bellvis L, Fontanillo C et al (2012) Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays. Modern Pathol 25(4):590–601CrossRef
Zurück zum Zitat Nagashima I, Takada T et al (2004) A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg 11(2):79–83PubMedCrossRef Nagashima I, Takada T et al (2004) A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg 11(2):79–83PubMedCrossRef
Zurück zum Zitat Nash GM, Gimbel M et al (2010) KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 17(2):572–578PubMedCrossRef Nash GM, Gimbel M et al (2010) KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 17(2):572–578PubMedCrossRef
Zurück zum Zitat Nordlinger B, Guiguet M et al (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77(7):1254–1262PubMedCrossRef Nordlinger B, Guiguet M et al (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77(7):1254–1262PubMedCrossRef
Zurück zum Zitat Pilgrim CH, Thomson BN et al (2012) The developing clinical problem of chemotherapy-induced hepatic injury. ANZ J Surg 82(1–2):23–29PubMedCrossRef Pilgrim CH, Thomson BN et al (2012) The developing clinical problem of chemotherapy-induced hepatic injury. ANZ J Surg 82(1–2):23–29PubMedCrossRef
Zurück zum Zitat Reddy SK, Tsung A et al (2012) Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases? J Surg Oncol 105(1):55–59PubMedCrossRef Reddy SK, Tsung A et al (2012) Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases? J Surg Oncol 105(1):55–59PubMedCrossRef
Zurück zum Zitat Rees M, Tekkis PP et al (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247(1):125–135PubMedCrossRef Rees M, Tekkis PP et al (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247(1):125–135PubMedCrossRef
Zurück zum Zitat Robinson SM, Wilson CH et al (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19(13):4287–4299PubMedCrossRef Robinson SM, Wilson CH et al (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19(13):4287–4299PubMedCrossRef
Zurück zum Zitat Settmacher U, Dittmar Y et al (2011) Predictors of long-term survival in patients with colorectal liver metastases: a single center study and review of the literature. Int J Colorectal Dis 26(8):967–981PubMedCrossRef Settmacher U, Dittmar Y et al (2011) Predictors of long-term survival in patients with colorectal liver metastases: a single center study and review of the literature. Int J Colorectal Dis 26(8):967–981PubMedCrossRef
Zurück zum Zitat Shimada H, Tanaka K et al (2009) Treatment for colorectal liver metastases: a review. Langenbeck’s Arch Surg 394(6):973–983CrossRef Shimada H, Tanaka K et al (2009) Treatment for colorectal liver metastases: a review. Langenbeck’s Arch Surg 394(6):973–983CrossRef
Zurück zum Zitat Small RM, Lubezky N et al (2009) Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 99(2):93–98PubMedCrossRef Small RM, Lubezky N et al (2009) Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 99(2):93–98PubMedCrossRef
Zurück zum Zitat Tamandl D, Klinger M et al (2011) Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 18(2):421–430PubMedCrossRef Tamandl D, Klinger M et al (2011) Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 18(2):421–430PubMedCrossRef
Zurück zum Zitat Tanaka T, Watanabe T et al (2009) Chromosome 18q deletion as a novel molecular predictor for colorectal cancer with simultaneous hepatic metastasis. Diagn Mol Pathol 18(4):219–225PubMedCrossRef Tanaka T, Watanabe T et al (2009) Chromosome 18q deletion as a novel molecular predictor for colorectal cancer with simultaneous hepatic metastasis. Diagn Mol Pathol 18(4):219–225PubMedCrossRef
Zurück zum Zitat Vogelaar FJ, Mesker WE et al (2010) Clinical impact of different detection methods for disseminated tumor cells in bone marrow of patients undergoing surgical resection of colorectal liver metastases: a prospective follow-up study. BMC Cancer 10:153PubMedCrossRef Vogelaar FJ, Mesker WE et al (2010) Clinical impact of different detection methods for disseminated tumor cells in bone marrow of patients undergoing surgical resection of colorectal liver metastases: a prospective follow-up study. BMC Cancer 10:153PubMedCrossRef
Zurück zum Zitat Zeitoun G, Buecher B et al (2006) Retention of chromosome arm 5q in stage II colon cancers identifies 83 % of liver metastasis occurrences. Genes Chromosom Cancer 45(1):94–102PubMedCrossRef Zeitoun G, Buecher B et al (2006) Retention of chromosome arm 5q in stage II colon cancers identifies 83 % of liver metastasis occurrences. Genes Chromosom Cancer 45(1):94–102PubMedCrossRef
Metadaten
Titel
Loss of chromosome 4 correlates with better long-term survival and lower relapse rate after R0-resection of colorectal liver metastases
verfasst von
Nadine Aust
Silke Schüle
Annelore K. Altendorf-Hofmann
Yuan Chen
Thomas Knösel
Olaf Dirsch
Utz Settmacher
Anja Weise
Kristin Mrasek
Thomas Liehr
Publikationsdatum
01.11.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-013-1505-2

Weitere Artikel der Ausgabe 11/2013

Journal of Cancer Research and Clinical Oncology 11/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.